Synthesis Towards Straight Chain Borinic Acids as Potential HIV-1 Protease Inhibitors
Document Type
Oral Presentation
Campus where you would like to present
SURC Ballroom C/D
Start Date
16-5-2013
End Date
16-5-2013
Abstract
There are 34 million people currently infected with HIV. The only treatment available involves merely slowing the development of HIV into AIDS. This is done with a cocktail of antiretroviral drugs. A drug of this type is a protease inhibitor. HIV-1 protease is an enzyme responsible for the release of mature HIV viral particles into the body. A cocktail of drugs is necessary because the virus will continually mutate and develop resistance to the antiretroviral drug. HIV-1 protease eventually becomes resistant to the inhibitors and new inhibitors are needed. The goal of this research is to develop a synthesis for a potential HIV-1 protease inhibitor which mimics the transition state analog of the natural substrate, and in turn interferes with the viral life cycle. These boronated compounds should provide better HIV treatment that has fewer side effects, increased affinity for the enzyme, and demonstrates greater affinity for the mutated forms of the enzyme as well.
Recommended Citation
Contreras, Erik, "Synthesis Towards Straight Chain Borinic Acids as Potential HIV-1 Protease Inhibitors" (2013). Symposium Of University Research and Creative Expression (SOURCE). 121.
https://digitalcommons.cwu.edu/source/2013/posters/121
Poster Number
46
Additional Mentoring Department
Chemistry
Synthesis Towards Straight Chain Borinic Acids as Potential HIV-1 Protease Inhibitors
SURC Ballroom C/D
There are 34 million people currently infected with HIV. The only treatment available involves merely slowing the development of HIV into AIDS. This is done with a cocktail of antiretroviral drugs. A drug of this type is a protease inhibitor. HIV-1 protease is an enzyme responsible for the release of mature HIV viral particles into the body. A cocktail of drugs is necessary because the virus will continually mutate and develop resistance to the antiretroviral drug. HIV-1 protease eventually becomes resistant to the inhibitors and new inhibitors are needed. The goal of this research is to develop a synthesis for a potential HIV-1 protease inhibitor which mimics the transition state analog of the natural substrate, and in turn interferes with the viral life cycle. These boronated compounds should provide better HIV treatment that has fewer side effects, increased affinity for the enzyme, and demonstrates greater affinity for the mutated forms of the enzyme as well.
Faculty Mentor(s)
Levente Fabry-Asztalos